Referências
Principais artigos
Lundberg IE, Fujimoto M, Vencovsky J, et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021 Dec 2;7(1):86. Resumo
Schmidt J. Current classification and management of inflammatory myopathies. J Neuromuscul Dis. 2018;5(2):109-29.Texto completo Resumo
Oldroyd A, Lilleker J, Chinoy H. Idiopathic inflammatory myopathies: a guide to subtypes, diagnostic approach and treatment. Clin Med (Lond). 2017 Jul;17(4):322-8.Texto completo Resumo
Oldroyd AGS, Lilleker JB, Amin T, et al. British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. Rheumatology (Oxford). 2022 May 5;61(5):1760-8.Texto completo Resumo
Artigos de referência
1. Khoo T, Lilleker JB, Thong BY, et al. Epidemiology of the idiopathic inflammatory myopathies. Nat Rev Rheumatol. 2023 Nov;19(11):695-712. Resumo
2. Ashton C, Paramalingam S, Stevenson B, et al. Idiopathic inflammatory myopathies: a review. Intern Med J. 2021 Jun;51(6):845-52.Texto completo Resumo
3. Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017 Dec;76(12):1955-64.Texto completo Resumo
4. Lundberg IE, Fujimoto M, Vencovsky J, et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021 Dec 2;7(1):86. Resumo
5. Okiyama N. Clinical features and cutaneous manifestations of juvenile and adult patients of dermatomyositis associated with myositis-specific autoantibodies. J Clin Med. 2021 Apr 16;10(8):1725.Texto completo Resumo
6. McHugh NJ, Tansley SL. Autoantibodies in myositis. Nat Rev Rheumatol. 2018 Apr 20;14(5):290-302. Resumo
7. Shah M, Shinjo SK, Day J, et al. Cardiovascular manifestations in idiopathic inflammatory myopathies. Clin Rheumatol. 2023 Oct;42(10):2557-75.Texto completo Resumo
8. Oddis CV, Conte CG, Steen VD, et al. Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982. J Rheumatol. 1990;17:1329-1334. Resumo
9. Medsger TA, Dawson WN Jr, Masi AT. The epidemiology of polymyositis. Am J Med. 1970;48:715-723. Resumo
10. Christopher-Stine L, Plotz PH. Adult inflammatory myopathies. Best Pract Res Clin Rheumatol. 2004;18:331-344. Resumo
11. Dorph C, Lundberg IE. Idiopathic inflammatory myopathies - myositis. Best Pract Res Clin Rheumatol. 2002;16:817-832. Resumo
12. Vivekanandam V, Bugiardini E, Merve A, et al. Differential diagnoses of inclusion body myositis. Neurol Clin. 2020 Aug;38(3):697-710. Resumo
13. Oflazer PS, Deymeer F, Parman Y. Sporadic-inclusion body myositis (s-IBM) is not so prevalent in Istanbul/Turkey: a muscle biopsy based survey. Acta Myol. 2011 Jun;30(1):34-6.Texto completo Resumo
14. Shelly S, Mielke MM, Mandrekar J, et al. Epidemiology and natural history of inclusion body myositis: a 40-year population-based study. Neurology. 2021 May 25;96(21):e2653-61. Resumo
15. Day J, Otto S, Proudman S, et al. Dysregulated innate immune function in the aetiopathogenesis of idiopathic inflammatory myopathies. Autoimmun Rev. 2017 Jan;16(1):87-95. Resumo
16. Dalakas MC. Pathogenesis and therapies of immune-mediated myopathies. Autoimmun Rev. 2012 Jan;11(3):203-6. Resumo
17. Moran EM, Mastaglia FL. Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications. Clin Exp Immunol. 2014 Dec;178(3):405-15.Texto completo Resumo
18. Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015 Apr 30;372(18):1734-47. Resumo
19. Schiffenbauer A, Faghihi-Kashani S, O'Hanlon TP, et al. The effect of cigarette smoking on the clinical and serological phenotypes of polymyositis and dermatomyositis. Semin Arthritis Rheum. 2018 Dec;48(3):504-12.Texto completo Resumo
20. Carpenter S, Karpati G. Pathology of skeletal muscle. 2nd ed. New York, NY: Oxford University Press USA; 2001.
21. Dalakas MC. Inflammatory, immune, and viral aspects of inclusion-body myositis. Neurology. 2006;66(2 suppl 1):S33-S38. Resumo
22. Chou SM. Inclusion body myositis: a chronic persistent mumps myositis? Hum Pathol. 1986;17:765-777. Resumo
23. Dalakas MC, Pezeshkpour GH, Gravell M, et al. Polymyositis associated with AIDS retrovirus. JAMA. 1986 Nov 7;256(17):2381-3. Resumo
24. Dalakas MC, Rakocevic G, Shatunov A, et al. Inclusion body myositis with human immunodeficiency virus infection: four cases with clonal expansion of viral-specific T cells. Ann Neurol. 2007;61:466-475. Resumo
25. Saud A, Naveen R, Aggarwal R, et al. COVID-19 and myositis: what we know so far. Curr Rheumatol Rep. 2021 Jul 3;23(8):63.Texto completo Resumo
26. Kharouf F, Kenig A, Bohbot E, et al. Increased rates of idiopathic inflammatory myopathies during the COVID-19 pandemic: a single-centre experience. Clin Exp Rheumatol. 2023 Mar;41(2):316-21. Resumo
27. Karpati G, Hilton-Jones D, Griggs RC. Disorders of voluntary muscle. 7th ed. Cambridge, UK: Cambridge University Press; 2001.
28. Reed AM, Ytterberg SR. Genetic and environmental risk factors for idiopathic inflammatory myopathies. Rheum Dis Clin North Am. 2002 Nov;28(4):891-916. Resumo
29. Caughey GE, Gabb GM, Ronson S, et al. Association of statin exposure with histologically confirmed idiopathic inflammatory myositis in an Australian population. JAMA Intern Med. 2018 Sep 1;178(9):1224-9.Texto completo Resumo
30. Seidler AM, Gottlieb AB. Dermatomyositis induced by drug therapy: a review of case reports. J Am Acad Dermatol. 2008;59:872-880. Resumo
31. Close RM, Close LM, Galdun P, et al. Potential implications of six American Indian patients with myopathy, statin exposure and anti-HMGCR antibodies. Rheumatology (Oxford). 2021 Feb 1;60(2):692-8.Texto completo Resumo
32. Basharat P, Lahouti AH, Paik JJ, et al. Statin-induced anti-HMGCR-associated myopathy. J Am Coll Cardiol. 2016 Jul 12;68(2):234-5.Texto completo Resumo
33. Hamada N, Maeda A, Takase-Minegishi K, et al. Incidence and distinct features of immune checkpoint inhibitor-related myositis from idiopathic inflammatory myositis: a single-center experience with systematic literature review and meta-analysis. Front Immunol. 2021;12:803410.Texto completo Resumo
34. Opinc-Rosiak AH, Makowska JS. Environmental exposures as risk factors for idiopathic inflammatory myopathies. J Autoimmun. 2023 Nov;140:103095.Texto completo Resumo
35. Shelly S, Triplett JD, Pinto MV, et al. Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy. Brain Commun. 2020;2(2):fcaa181.Texto completo Resumo
36. Monaghan M, Loh C, Jones S, et al. Inflammatory myositis secondary to anti-retroviral therapy in a child; case Rreport and review of the literature. J Neuromuscul Dis. 2021;8(6):1089-95. Resumo
37. Syrmou V, Liaskos C, Ntavari N, et al. COVID-19 vaccine-associated myositis: a comprehensive review of the literature driven by a case report. Immunol Res. 2023 Aug;71(4):537-46.Texto completo Resumo
38. Ferri C, Colaci M, Manzini CU, et al. Polymyositis following Pandemic Influenza A (H1N1) and 2009-10 Seasonal Trivalent Vaccines. Case Rep Rheumatol. 2012;2012:836930.Texto completo Resumo
39. Altman A, Szyper-Kravitz M, Shoenfeld Y. HBV vaccine and dermatomyositis: is there an association? Rheumatol Int. 2008 Apr;28(6):609-12. Resumo
40. Chinoy H, Adimulam S, Marriage F, et al. Interaction of HLA-DRB1*03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study. Ann Rheum Dis. 2012 Jun;71(6):961-5.Texto completo Resumo
41. Okada S, Weatherhead E, Targoff IN, et al. Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis Rheum. 2003 Aug;48(8):2285-93.Texto completo Resumo
42. Limaye V, Blumbergs P, Scott G et al. The epidemiology of dermatomyositis in South Australia. APLAR J. Rheumatol. 2007 May 15;10(2):94-100.
43. Svensson J, Arkema EV, Lundberg IE, et al. Incidence and prevalence of idiopathic inflammatory myopathies in Sweden: a nationwide population-based study. Rheumatology (Oxford). 2017 May 1;56(5):802-10.Texto completo Resumo
44. O'Hanlon T, Koneru B, Bayat E, et al. Immunogenetic differences between Caucasian women with and those without silicone implants in whom myositis develops. Arthritis Rheum. 2004 Nov;50(11):3646-50.Texto completo Resumo
45. Selva-O'Callaghan A, Tura JM, Grau-Junyent JM, et al. Silicone gel filled breast implants and dermatomyositis. Clin Exp Rheumatol. 2004 May-Jun;22(3):376. Resumo
46. Limaye S, Limaye V. Clinical characteristics of myositis associated with graft-versus-host disease. Curr Rheumatol Rep. 2021 Apr 24;23(5):30. Resumo
47. Reed AM, McNallan K, Wettstein P, et al. Does HLA-dependent chimerism underlie the pathogenesis of juvenile dermatomyositis? J Immunol. 2004 Apr 15;172(8):5041-6.Texto completo Resumo
48. Chanbour H, Jiblawi A, Aboudalle A, et al. Association of silicosis and dermatomyositis: case report and literature review. Cureus. 2021 Nov;13(11):e19875.Texto completo Resumo
49. Christopher-Stine L, Plotz PH. Myositis: an update on pathogenesis. Curr Opin Rheumatol. 2004 Nov;16(6):700-6. Resumo
50. Rothwell S, Cooper RG, Lundberg IE, et al. Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. Ann Rheum Dis. 2016 Aug;75(8):1558-66. Resumo
51. Rothwell S, Chinoy H, Lamb JA, et al. Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. Ann Rheum Dis. 2019 Jul;78(7):996-1002.Texto completo Resumo
52. Rothwell S, Cooper RG, Lundberg IE, et al. Immune-array analysis in sporadic inclusion body myositis reveals HLA-DRB1 amino acid heterogeneity across the myositis spectrum. Arthritis Rheumatol. 2017 May;69(5):1090-9.Texto completo Resumo
53. Lamb JA. The genetics of autoimmune myositis. Front Immunol. 2022;13:886290.Texto completo Resumo
54. Rothwell S, Amos CI, Miller FW, et al. Identification of novel associations and localization of signals in idiopathic inflammatory myopathies using genome-wide imputation. Arthritis Rheumatol. 2023 Jun;75(6):1021-7.Texto completo Resumo
55. Kochi Y, Kamatani Y, Kondo Y, et al. Splicing variant of WDFY4 augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. Ann Rheum Dis. 2018 Apr;77(4):602-11. Resumo
56. Chan SH, Bylstra Y, Teo JX, et al. Analysis of clinically relevant variants from ancestrally diverse Asian genomes. Nat Commun. 2022 Nov 5;13(1):6694.Texto completo Resumo
57. Dourado E, Bottazzi F, Cardelli C, et al. Idiopathic inflammatory myopathies: one year in review 2022. Clin Exp Rheumatol. 2023 Mar;41(2):199-213. Resumo
58. Lundberg IE, Miller FW, Tjärnlund A, et al. Diagnosis and classification of idiopathic inflammatory myopathies. J Intern Med. 2016 Jul;280(1):39-51.Texto completo Resumo
59. Banker BQ. Dermatomyostis of childhood, ultrastructural alterations of muscle and intramuscular blood vessels. J Neuropathol Exp Neurol. 1975;34:46-75. Resumo
60. Carpenter S, Karpati G, Rothman S, et al. The childhood type of dermatomyositis. Neurology. 1976;26:952-962. Resumo
61. Dalakas MC. Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Curr Opin Neurol. 2004;17:561-567. Resumo
62. Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med. 1991 Nov 21;325(21):1487-98. Resumo
63. Choi YC, Dalakas MC. Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies. Neurology. 2000;54:65-71. Resumo
64. Lindvall B, Dahlbom K, Henriksson KG, et al. The expression of adhesion molecules in muscle biopsies: the LFA-1/VLA-4 ratio in polymyositis. Acta Neurol Scand. 2003;107:134-141. Resumo
65. Snedden AM, Kellett KAB, Lilleker JB, et al. The role of protein aggregation in the pathogenesis of inclusion body myositis. Clin Exp Rheumatol. 2022 Feb;40(2):414-24. Resumo
66. Dalakas MC. Sporadic inclusion body myositis--diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol. 2006 Aug;2(8):437-47. Resumo
67. Rönnblom L, Eloranta ML. The interferon signature in autoimmune diseases. Curr Opin Rheumatol. 2013 Mar;25(2):248-53. Resumo
68. Arshanapalli A, Shah M, Veerula V, et al. The role of type I interferons and other cytokines in dermatomyositis. Cytokine. 2015 Jun;73(2):319-25. Resumo
69. Zampieri S, Ghirardello A, Iaccarino L, et al. Polymyositis-dermatomyositis and infections. Autoimmunity. 2006 May;39(3):191-6. Resumo
70. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010 May;11(5):373-84.Texto completo Resumo
71. Baccala R, Hoebe K, Kono DH, et al. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med. 2007 May;13(5):543-51. Resumo
72. Schmidt J. Current classification and management of inflammatory myopathies. J Neuromuscul Dis. 2018;5(2):109-29.Texto completo Resumo
73. Preuße C, Goebel HH, Held J, et al. Immune-mediated necrotizing myopathy is characterized by a specific Th1-M1 polarized immune profile. Am J Pathol. 2012 Dec;181(6):2161-71.Texto completo Resumo
74. Oldroyd AGS, Callen JP, Chinoy H, et al. International guideline for idiopathic inflammatory myopathy-associated cancer screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative. Nat Rev Rheumatol. 2023 Dec;19(12):805-17.Texto completo Resumo
75. Rider LG, Koziol D, Giannini EH, et al. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken). 2010 Apr;62(4):465-72.Texto completo Resumo
76. Medical Research Council. Aids to the examination of the peripheral nervous system. 1976 [internet publication].Texto completo
77. Oldroyd A, Lilleker J, Chinoy H. Idiopathic inflammatory myopathies: a guide to subtypes, diagnostic approach and treatment. Clin Med (Lond). 2017 Jul;17(4):322-8.Texto completo Resumo
78. Lundberg I. Polymyositis and dermatomyositis. In: Bijlsma J, ed. Eular textbook on rheumatic diseases. 1st ed. London: BMJ Group; 2012: 568-93.
79. Lu X, Peng Q, Wang G. Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress. Nat Rev Rheumatol. 2024 Jan;20(1):48-62. Resumo
80. Chua CG, Low JZ, Lim WY, et al. Characteristics of anti-transcriptional intermediary factor 1 gamma autoantibody-positive dermatomyositis patients in Singapore. Ann Acad Med Singap. 2022 Dec;51(12):755-65.Texto completo Resumo
81. Dion E, Chérin P. Use of muscular MRI in inflammatory myopathies [in French]. Rev Med Interne. 2004;25:435-441. Resumo
82. Johnson SR, Bernstein EJ, Bolster MB, et al. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) guideline for the screening and monitoring of interstitial lung dsease in people with systemic autoimmune rheumatic diseases. Arthritis Care Res (Hoboken). 2024 Aug;76(8):1070-82.Texto completo Resumo
83. Lotz BP, Engel AG, Nishino H, et al. Inclusion body myositis. Observations in 40 patients. Brain. 1989;112:727-747. Resumo
84. Badrising UA, Maat-Schieman ML, van Houwelingen JC, et al. Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients. J Neurol. 2005;252:1448-1454. Resumo
85. Betteridge Z, McHugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med. 2016 Jul;280(1):8-23.Texto completo Resumo
86. Motomura K, Yamashita H, Yamada S, et al. Clinical characteristics and prognosis of polymyositis and dermatomyositis associated with malignancy: a 25-year retrospective study. Rheumatol Int. 2019 Oct;39(10):1733-9. Resumo
87. Engel A, Franzini-Armstrong C. Myology: basic and clinical. 3rd ed. New York: McGraw-Hill, Medical Publishing Division; 2004.
88. Al-Nahhas A, Jawad AS. PET/CT imaging in inflammatory myopathies. Ann N Y Acad Sci. 2011 Jun;1228:39-45. Resumo
89. Fan X, Rouleau GA. Progress in understanding the pathogenesis of oculopharyngeal muscular dystrophy. Can J Neurol Sci. 2003;30:8-14. Resumo
90. Rose MR; ENMC IBM Working Group. 188th ENMC international workshop: inclusion body myositis, 2-4 December 2011, Naarden, the Netherlands. Neuromuscul Disord. 2013 Dec;23(12):1044-55.Texto completo Resumo
91. The Myositis Association. Diagnostic criteria for necrotizing myopathy [internet publication].Texto completo
92. Colak A, Benli K, Dönmez T, et al. Papillary carcinoma of the sphenoid sinus associated with sphenoid sinus abscess presenting as cavernous sinus syndrome. A case report. J Clin Neuroophthalmol. 1990 Mar;10(1):18-20. Resumo
93. Oldroyd AGS, Lilleker JB, Amin T, et al. British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. Rheumatology (Oxford). 2022 May 5;61(5):1760-8.Texto completo Resumo
94. Johnson SR, Bernstein EJ, Bolster MB, et al. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases. Arthritis Rheumatol. 2024 Aug;76(8):1182-200.Texto completo Resumo
95. Lim J, Eftimov F, Verhamme C, et al. Intravenous immunoglobulins as first-line treatment in idiopathic inflammatory myopathies: a pilot study. Rheumatology (Oxford). 2021 Apr 6;60(4):1784-92.Texto completo Resumo
96. Lee H, Chung SJ, Kim SH, et al. Treatment outcomes of infectious and non-infectious acute exacerbation of myositis-related interstitial lung disease. Front Med (Lausanne). 2021;8:801206.Texto completo Resumo
97. Wiala A, Vujic I, Richter L, et al. Dermatomyositis requires long-term treatment with combined immunosuppressive and immunoglobulin therapy. J Dtsch Dermatol Ges. 2021 Mar;19(3):456-8. Resumo
98. Hoff LS, de Souza FHC, Miossi R, et al. Long-term effects of early pulse methylprednisolone and intravenous immunoglobulin in patients with dermatomyositis and polymyositis. Rheumatology (Oxford). 2022 Apr 11;61(4):1579-88.Texto completo Resumo
99. Schneider-Gold C, Hartung HP, Gold R. Mycophenolate mofetil and tacrolimus: new therapeutic options in neuroimmunological diseases. Muscle Nerve. 2006;34:284-291. Resumo
100. Dalakas MC. Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol. 2010;6:129-137. Resumo
101. Dalakas MC. Inflammatory myopathies: management of steroid resistance. Curr Opin Neurol. 2011 Oct;24(5):457-62. Resumo
102. Wiendl H. Idiopathic inflammatory myopathies: current and future therapeutic options. Neurotherapeutics. 2008;5:548-557. Resumo
103. Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65:314-324. Resumo
104. Fasano S, Gordon P, Hajji R, et al. Rituximab in the treatment of inflammatory myopathies: a review. Rheumatology (Oxford). 2017 Jan;56(1):26-36.Texto completo Resumo
105. Valiyil R, Casciola-Rosen L, Hong G, et al. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res (Hoboken). 2010 Sep;62(9):1328-34.Texto completo Resumo
106. Mok CC, Ho LY, To CH. Rituximab for refractory polymyositis: an open-label prospective study. J Rheumatol. 2007 Sep;34(9):1864-8. Resumo
107. Ge Y, Li S, Tian X, et al. Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy. Clin Rheumatol. 2021 Jun;40(6):2311-7. Resumo
108. Amato AA, Griggs RC. Treatment of idiopathic inflammatory myopathies. Curr Opin Neurol. 2003 Oct;16(5):569-75. Resumo
109. Tjärnlund A, Tang Q, Wick C, et al. Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. Ann Rheum Dis. 2018 Jan;77(1):55-62. Resumo
110. Connolly CM, Gupta L, Fujimoto M, et al. Idiopathic inflammatory myopathies: current insights and future frontiers. Lancet Rheumatol. 2024 Feb;6(2):e115-27. Resumo
111. Paik JJ, Shneyderman M, Gutierrez-Alamillo L, et al. Long-term extension study of tofacitinib in refractory dermatomyositis. Arthritis Rheumatol. 2022 Feb;74(2):371-2. Resumo
112. ClinicalTrials.gov. Baricitinib in patients with relapsing or naïve dermatomyositis (BIRD). ClinicalTrials.gov Identifier: NCT04972760. Mar 2024 [internet publication].Texto completo
113. ClinicalTrials.gov. Baricitinib in the treatment of new-onset juvenile dermatomyositis (MYOCIT) (MYOCIT). ClinicalTrials.gov Identifier: NCT05524311. Jan 2024 [internet publication].Texto completo
114. Chen Z, Wang X, Ye S. Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease. N Engl J Med. 2019 Jul 18;381(3):291-3. Resumo
115. Shirai T, Machiyama T, Sato H, et al. Intensive induction therapy combining tofacitinib, rituximab and plasma exchange in severe anti-melanoma differentiation-associatedprotein-5 antibody-positive dermatomyositis. Clin Exp Rheumatol. 2023 Mar;41(2):291-300. Resumo
116. Fan L, Lyu W, Liu H, et al. A retrospective analysis of outcome in melanoma differentiation-associated gene 5-related interstitial lung disease treated with Ttofacitinib or tacrolimus. J Rheumatol. 2022 Dec;49(12):1356-64.Texto completo Resumo
117. Peter HH, Ochs HD, Cunningham-Rundles C, et al. Targeting FcRn for immunomodulation: benefits, risks, and practical considerations. J Allergy Clin Immunol. 2020 Sep;146(3):479-91.e5.Texto completo Resumo
118. ClinicalTrials.gov. A study of nipocalimab in participants with active idiopathic inflammatory myopathies (SPIREA). ClinicalTrials.gov Identifier: NCT05379634. Jul 2024 [internet publication].Texto completo
119. ClinicalTrials.gov. A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with active idiopathic inflammatory myopathy (ALKIVIA+). ClinicalTrials.gov Identifier: NCT05979441. Jul 2024 [internet publication].Texto completo
120. ClinicalTrials.gov. A study to investigate the efficacy and safety of efgartigimod PH20 SC in adult participants with active idiopathic inflammatory myopathy. (ALKIVIA). ClinicalTrials.gov Identifier: NCT05523167. Jul 2024 [internet publication].Texto completo
121. Wilfong EM, Aggarwal R. Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease. Ther Adv Musculoskelet Dis. 2021;13:1759720X211060907.Texto completo Resumo
122. Li T, Guo L, Chen Z, et al. Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis. Sci Rep. 2016 Sep 12;6:33226.Texto completo Resumo
123. Liang J, Cao H, Yang Y, et al. Efficacy and tolerability of nintedanib in idiopathic-inflammatory-myopathy-related interstitial lung disease: a pilot study. Front Med (Lausanne). 2021;8:626953.Texto completo Resumo
124. Goel N, Needham M, Soler-Ferran D, et al. POS1342 Depletion of KLRG1+ T cells in a first-in-human clinical trial of ABC008 in inclusion body myositis (IBM). Nature. 2017 Oct 19;550(7676):407-10.
125. Benveniste O, Hogrel JY, Belin L, et al. Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial. Lancet Rheumatol. 2021 Jan;3(1):e40-8. Resumo
126. Lyu X, Gupta L, Tholouli E, et al. Chimeric antigen receptor T cell therapy: a new emerging landscape in autoimmune rheumatic diseases. Rheumatology (Oxford). 2024 May 2;63(5):1206-16.Texto completo Resumo
127. Schett G, Mackensen A, Mougiakakos D. CAR T-cell therapy in autoimmune diseases. Lancet. 2023 Nov 25;402(10416):2034-44. Resumo
128. ClinicalTrials.gov. IMPT-514 in systemic lupus erythematosus, anca-associated vasculitis, and idiopathic inflammatory myopathy. ClinicalTrials.gov Identifier: NCT06462144. Jul 2024 [internet publication].Texto completo
129. Dobloug GC, Svensson J, Lundberg IE, et al. Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study. Ann Rheum Dis. 2018 Jan;77(1):40-7. Resumo
130. Sultan SM, Ioannou Y, Moss K, et al. Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford). 2002;41:22-26.Texto completo Resumo
131. Marie I, Hachulla E, Hatron PY, et al. Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol. 2001;28:2230-2237. Resumo
132. So J, So H, Wong VT, et al. Predictors of rapidly progressive interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis. Rheumatology (Oxford). 2022 Nov 2;61(11):4437-44.Texto completo Resumo
133. Limaye V, Hakendorf P, Woodman RJ, et al. Mortality and its predominant causes in a large cohort of patients with biopsy-determined inflammatory myositis. Intern Med J. 2012 Feb;42(2):191-8.Texto completo Resumo
134. Briani C, Doria A, Sarzi-Puttini P, et al. Update on idiopathic inflammatory myopathies. Autoimmunity. 2006;39:161-170. Resumo
135. de Merieux P, Verity MA, Clements PJ, et al. Esophageal abnormalities and dysphagia in polymyositis and dermatomyositis. Arthritis Rheum. 1983 Aug;26(8):961-8. Resumo
136. Kagen LJ, Hochman RB, Strong EW. Cricopharyngeal obstruction in inflammatory myopathy (polymyositis/dermatomyositis). Report of three cases and review of the literature. Arthritis Rheum. 1985;28:630-636. Resumo
137. Madan V, Chinoy H, Griffiths CE, et al. Defining cancer risk in dermatomyositis: part I. Clin Exp Dermatol. 2009 Jun;34(4):451-5. Resumo
138. Buchbinder R, Forbes A, Hall S, et al. Incidence of malignant disease in biopsy-proven inflammatory myopathy: a population-based cohort study. Ann Intern Med. 2001 Jun 19;134(12):1087-95. Resumo
139. Wakata N, Kurihara T, Saito E, et al. Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol. 2002 Nov;41(11):729-34. Resumo
140. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001 Jan 13;357(9250):96-100. Resumo
141. Callen JP. Relation between dermatomyositis and polymyositis and cancer. Lancet. 2001 Jan 13;357(9250):85-6. Resumo
142. Greenberg SA, Amato AA. Inflammatory myopathy associated with mixed connective tissue disease and scleroderma renal crisis. Muscle Nerve. 2001 Nov;24(11):1562-6. Resumo
O uso deste conteúdo está sujeito ao nosso aviso legal